Literature DB >> 17152199

Therapeutic transarterial embolisation in the management of benign and malignant renal conditions.

B K Somani1, G Nabi, P Thorpe, J Hussey, S McClinton.   

Abstract

PURPOSE: The aim of this study was to critically appraise the efficacy and complications of Therapeutic Transarterial Embolisation (TAE) in various benign and malignant renal conditions.
MATERIAL AND METHODS: The records of all patients who underwent renal embolisation procedures, at a single institution, between March 1992 and March 2004, were reviewed. The patients were identified from hospital records via the procedure coding system and the radiology department procedures book and were analysed retrospectively. Twenty-nine patients were analysed, looking at indications, clinical outcome, complications and long-term results.
RESULTS: Twenty-nine patients underwent 35 embolisation procedures during this period. Fourteen patients with benign diseases underwent 17 embolisation procedures for haematuria or intractable pain. In the haematuria group, selective embolisation was used to treat bleeding post percutaneous nephrolithotomy (PCNL) (n=4), angiomyolipoma (n=2), arteriovenous (AV) malformation (n=l1), renal artery aneurysm (n=1) and renal trauma (n=2). In the renal pain group (n=3), non-selective embolisation was done. Two of these patients had recurrence of pain despite repeat embolisation and subsequently underwent nephrectomy. Fifteen patients with advanced renal malignancy, who were deemed unfit for surgery, underwent 18 embolisation procedures for symptomatic haematuria. Twelve of the 15 patients had successful outcomes with cessation of haematuria. Three patients required repeat embolisation procedures for continuing haematuria with success. There were no major embolisation-related complications. Minor complications were self-limiting and settled with conservative management.
CONCLUSION: Renal artery embolisation is effective in managing haematuria in benign and malignant renal conditions where indicated, with minor and easily treatable adverse effects

Entities:  

Mesh:

Year:  2006        PMID: 17152199     DOI: 10.1016/s1479-666x(06)80110-1

Source DB:  PubMed          Journal:  Surgeon        ISSN: 1479-666X            Impact factor:   2.392


  7 in total

1.  Multimodal approach to the endovascular treatment of embolisation or exclusion of the renal arteries and their distal and/or polar branches: personal experience.

Authors:  F Pozzi-Mucelli; A Medeot; S Cernic; A Calgaro; M Braini; M Cova
Journal:  Radiol Med       Date:  2011-04-19       Impact factor: 3.469

2.  [Foreign body in proximal ureter after selective embolisation of a renal artery].

Authors:  S Blaut; H Zecha; M Schneider; S Druschel; M Werner; J Lohmann; F Steinbach
Journal:  Urologe A       Date:  2008-12       Impact factor: 0.639

3.  Gross hematuria caused by a congenital intrarenal arteriovenous malformation: a case report.

Authors:  Gianpaolo Carrafiello; Domenico Laganà; Gaia Peroni; Monica Mangini; Federico Fontana; Davide Mariani; Gabriele Piffaretti; Carlo Fugazzola
Journal:  J Med Case Rep       Date:  2011-10-08

4.  Polycystic kidney disease: inheritance, pathophysiology, prognosis, and treatment.

Authors:  Christian R Halvorson; Matthew S Bremmer; Stephen C Jacobs
Journal:  Int J Nephrol Renovasc Dis       Date:  2010-06-24

5.  Varicocele due to renal arteriovenous malformation mimicking a renal tumor: a case report.

Authors:  Peng-Chao Li; Jia-Yi Zhang; Yan-Yan Xiu; Sheng Liu; Jin-Guo Xia; Hai-Bin Shi; Ning-Hong Song
Journal:  J Med Case Rep       Date:  2018-01-05

6.  Massive hematuria due to a congenital renal arteriovenous malformation mimicking a renal pelvis tumor: a case report.

Authors:  P Sountoulides; I Zachos; K Paschalidis; I Asouhidou; A Fotiadou; A Bantis; M Palasopoulou; T Podimatas
Journal:  J Med Case Rep       Date:  2008-05-05

7.  Emergency Transcatheter Arterial Embolization for Acute Renal Hemorrhage.

Authors:  Hong Liang Wang; Chun Yang Xu; Hong Hui Wang; Wei Xu
Journal:  Medicine (Baltimore)       Date:  2015-10       Impact factor: 1.817

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.